A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro

Laboratory Investigation

Volumn 93, Issue 5, 2013, Pages 528-542

  Myungjin Lee, Janet ^a   Mhawech Fauceglia, Paulette ^a   Lee, Nathan ^a   Cristina Parsanian, Lucineh ^a   Gail Lin, Yvonne ^a   Andrew Gayther, Simon ^a   Lawrenson, Kate ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cell adhesion; chemoresistance; chemoresponse; epithelial ovarian cancer; microenvironment; three dimensional modeling

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CYTOSKELETON PROTEIN; PACLITAXEL; PLASTIC; POLYHYDROXOETHYLAMETHACRYLATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84877255483     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.41     Document Type: Article

References (65)

1. Ashworth A, Balkwill F, Bast RC, et al. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 2008;108:652-657.
2. Ma XH, Piao S, Wang D, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 2011;17:3478-3489.
3. Smalley KS, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-1144.
4. dit Faute MA, Laurent L, Ploton D, et al. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002;19:161-168.
5. Weigelt B, Lo AT, Park CC, et al. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010;122:35-43.
6. Barcellos-Hoff MH, Aggeler J, Ram TG, et al. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 1989;105:223-235.
7. Tokuda Y, Nakamura Y, Suzuki A, et al. A new high-yield continuous cell-culture system for lymphokine-activated killer cells. Cancer Immunol Immunother 1989;30:1-4.
8. Khaoustov VI, Darlington GJ, Soriano HE, et al. Induction of threedimensional assembly of human liver cells by simulated microgravity. In Vitro Cell Dev Biol Anim 1999;35:501-509.
9. Lawrenson K, Benjamin E, Turmaine M, et al. In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif 2009;42:385-393.
10. Hutmacher DW. Scaffold design and fabrication technologies for engineering tissues-state of the art and future perspectives. J Biomater Sci Polym Ed 2001;12:107-124.
11. Ghosh S, Spagnoli GC, Martin I, et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005;204: 522-531.
12. Gómez-Lechón MJ, Jover R, Donato T, et al. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J Cell Physiol 1998;177:553-562.
13. Delcommenne M, Streuli CH. Control of integrin expression by extracellular matrix. J Biol Chem 1995;270:26794-26801.
14. Kenny PA, Lee GY, Myers CA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007;1:84-96.
15. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 2011;14:191-201.
16. Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:29.
17. Friedrich J, Seidel C, Ebner R, et al. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009;4:309-324.
18. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
19. Wright JD, Secord AA, Numnum TM, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18:400-406.
20. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516.
21. Eva A, Robbins KC, Andersen PR, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 1982;295:116-119.
22. Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070-3074.
23. Louie KG, Behrens BC, Kinsella TJ, et al. Radiation survival parameters of antineoplastic drug-sensitive and-resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985;45:2110-2115.
24. Buick RN, Pullano R, Trent JM, et al. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45: 3668-3676.
25. van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, et al. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 1993;53:613-620.
26. Simon WE, Albrecht M, Hänsel M, et al. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983;70:839-845.
27. Lau DH, Lewis AD, Ehsan MN, et al. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991;51: 5181-5187.
28. Mills GB, May C, Hill M, et al. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990;86: 851-855.
29. Bénard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-4979.
30. Ward BG, Wallace K, Shepherd JH, et al. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 1987;47:2662-2667.
31. Mistry P, Kelland LR, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-220.
32. Wilson AP. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst 1984;72:513-521.
33. Alama A, Barbieri F, Favre A, et al. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Gynecol Oncol 1996;62:82-88.
34. DiSaia PJ, Sinkovics JG, Rutledge FN, et al. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol 1972;114:979-989.
35. Andrews PA, Albright KD. Mitochondrial defects in cisdiamminedichloroplatinum( II)-resistant human ovarian carcinoma cells. Cancer Res 1992;52:1895-1901.
36. Bast Jr RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68: 1331-1337.
37. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-5389.
38. Hamilton TC, Lai GM, Rothenberg ML, et al. Mechanisms of resistance to cisplatin and alkylating agents. Cancer Treat Res 1989;48:151-169.
39. Mö bus VJ, Moll R, Gerharz CD, et al. Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis. Br J Cancer 1994;69:422-428.
40. Hills CA, Kelland LR, Abel G, et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989;59:527-534.
41. Yu D, Wolf JK, Scanlon M, et al. Enhances c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53: 891-898.
42. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-361.
43. DelloRusso C, Welcsh PL, Wang W, et al. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 2007;5:35-45.
44. Kühn W, Kaufmann M, Feichter GE, et al. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecol Oncol 1989;33:360-367.
45. Shaw TJ, Senterman MK, Dawson K, et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-1042.
46. Korch C, Spillman MA, Jackson TA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 2012;127: 241-248.
47. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004;15:1535-1542.
48. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alphacatenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 1998;32:69-80.
49. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
50. Zietarska M, Maugard CM, Filali-Mouhim A, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007;46:872-885.
51. Barbolina MV, Adley BP, Kelly DL, et al. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer 2009;125:816-825.
52. Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009;124:2060-2070.
53. Kenny HA, Krausz T, Yamada SD, et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007;121:1463-1472.
54. Iwanicki MP, Davidowitz RA, Ng MR, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 2011;1:144-157.
55. Shepherd TG, Mujoomdar ML, Nachtigal MW. Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J Ovarian Res 2010;3:5.
56. Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One 2011;6:e18872.
57. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 2003;202:89-96.
58. Sundfeldt K, Piontkewitz Y, Ivarsson K, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 1997;74:275-280.
59. Dabbs DJ, Geisinger KR. Common epithelial ovarian tumors. Immunohistochemical intermediate filament profiles. Cancer 1988;62:368-374.
60. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-318.
61. Yang Z, Zhao X. A 3D model of ovarian cancer cell lines on peptide nanofiber scaffold to explore the cell-scaffold interaction and chemotherapeutic resistance of anticancer drugs. Int J Nanomedicine 2011;6:303-310.
62. Rizvi I, Celli JP, Evans CL, et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res 2010;70: 9319-9328.
63. Rahmanzadeh R, Rai P, Celli JP, et al. Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res 2010;70:9234-9242.
64. Evans CL, Abu-Yousif AO, Park YJ, et al. Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT. PLoS One 2011;6:e23434.
65. Loessner D, Stok KS, Lutolf MP, et al. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010;31:8494-8506.